Accession Number : ADB105385
Title : Chemotherapy of Leishmaniasis.
Descriptive Note : Final rept. 1 Jul 74-30 Sep 84,
Corporate Author : GEORGIA UNIV RESEARCH FOUNDATION INC ATHENS
Personal Author(s) : Hanson, William L. ; Chapman, Willie L., Jr. ; Waits, Virginia B.
Report Date : SEP 1984
Pagination or Media Count : 27
Abstract : A total of 3,746 compounds was tested for antileishmanial activity against three day infections of Leishmania donovani in golden hamsters. Twelve hundred fifty-three of these were significantly active (220 had activity greater than the reference compound, meglumine antimoniate (Glucantime); G indexes ranged from 1.53 to 700.00. Using various modifications of this test system to optimize the treatment regimen of selected promising compounds, the efficacy of Glucantime, WR06026, or formycin B was similar when administered in a single treatment, or in 2, a4, 8, or 16 treatments. These three compounds were highly efficacious but not curative when used alone, or in combination against visceral leishmaniasis. A total of 734 compounds was tested for antileishmanial activity against nineteen day infections of Leishmania braziliensis panamensis in golden hamsters. Using various modifications of the visceral or cutaneous leishmaniasis test systems, the antileishmanial efficacy of a total of 231 liposome preparations (liposome-encapsulated antimonial drugs or 8-aminoquinolines) was evaluated (225 against L. donovani and 6 against L. b. panamensis). Treatment of L. donovani infections in hamsters with incremental increases of Glucantime resulted in parasites resistant to dosage levels of Glucantime as high as 824 mg/kg/day (MKD). Dogs, owl monkeys, squirrel monkeys, and opossums were evaluated as animal models of visceral leishmaniasis and each species was determined useful for preclinical testing of promising antileishmanial drugs.
Descriptors : *CHEMOTHERAPY, *LEISHMANIASIS, ANIMALS, MODELS, SKIN DISEASES, DOGS, DOSAGE, LEVEL(QUANTITY), HAMSTERS, OWL MONKEYS, INFECTIOUS DISEASES, DRUGS, PARASITES, LEISHMANIA.
Subject Categories : Medicine and Medical Research
Distribution Statement : APPROVED FOR PUBLIC RELEASE